Generic Viramune XR Availability
See also: Generic Viramune
VIRAMUNE XR (nevirapine - tablet, extended release;oral)
Manufacturer: BOEHRINGER INGELHEIM
Approval date: March 25, 2011
Strength(s): 400MG [RLD]
Manufacturer: BOEHRINGER INGELHEIM
Approval date: November 8, 2012
Has a generic version of Viramune XR been approved?
No. There is currently no therapeutically equivalent version of Viramune XR available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viramune XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Extended release formulation of nevirapine
Issued: June 11, 2013
Assignee(s): Boehringer Ingelheim International GmbH
The invention relates to an extended release pharmaceutical composition comprising nevirapine.Patent expiration dates:
- March 12, 2029✓
- March 12, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 25, 2014 - NEW DOSAGE FORM
- November 8, 2015 - NEW PATIENT POPULATION
- Viramune XR extended-release tablets Consumer Information (Wolters Kluwer)
- Viramune XR Consumer Information (Cerner Multum)
- Viramune XR Advanced Consumer Information (Micromedex)
- Nevirapine Consumer Information (Wolters Kluwer)
- Nevirapine extended-release tablets Consumer Information (Wolters Kluwer)
- Nevirapine suspension Consumer Information (Wolters Kluwer)
- Nevirapine Consumer Information (Cerner Multum)
- Viramune O/S Advanced Consumer Information (Micromedex)
- Nevirapine Advanced Consumer Information (Micromedex)
- Nevirapine AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|